A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder.
Hyperarousal
Memory consolidation
Military trauma
Pharmacotherapy
Sleep quality
Time since trauma
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
27
09
2023
revised:
20
01
2024
accepted:
26
01
2024
pubmed:
14
2
2024
medline:
14
2
2024
entrez:
13
2
2024
Statut:
ppublish
Résumé
Sleep disturbances in posttraumatic stress disorder (PTSD) are a potential target for improving PTSD severity with pharmacotherapy. TNX-102 SL is a bedtime sublingual formulation of cyclobenzaprine with potent binding and antagonist activity at 5-HT
Identifiants
pubmed: 38350291
pii: S0165-1781(24)00049-0
doi: 10.1016/j.psychres.2024.115764
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115764Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest MP consulted with Tonix on the preparation, creation, and presentation of the published work. SL and GMS are employees of Tonix Pharmaceuticals, Inc. (Tonix) and own stock and/or have options in the company. JE is an employee of Tonix and previously consulted on the statistical analyses in the study. BV is the primary statistician consulting for Tonix as an employee of Rho, Inc. LLD has received income as consultant from Otsuka, Lundbeck, Signant Health, and Boehringer Ingelheim and has received research funding or materials from Tonix, Alkermes, Aptinyx, Social Finance, and Westat.